Who is sponsoring NCT05320120?

NCT05320120 is sponsored by Rupert Lanzenberger.

What drugs are being tested in NCT05320120?

Interventions in NCT05320120: 56mg esketamine (2x Spravato® 28 mg nasal spray), 0.9% saline solution nasal spray.

What condition does NCT05320120 study?

NCT05320120 studies Ketamine Treatment.

Is NCT05320120 still recruiting?

NCT05320120 is currently completed. Last updated 15 April 2024.

Last reviewed 2024-04-15 · How we verify

NCT05320120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI

Completed Phase 1 Last updated 15 April 2024

What this trial tests

Phase 1 trial testing 56mg esketamine (2x Spravato® 28 mg nasal spray) in Ketamine Treatment in 33 participants. Completed in 21 June 2023.

Timeline

1 June 2022

Primary endpoint
21 June 2023

21 June 2023

Quick facts

Lead sponsor	Rupert Lanzenberger
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	33
Start date	1 June 2022
Primary completion	21 June 2023
Estimated completion	21 June 2023
Sites	1 location across Austria

Drugs / interventions tested

56mg esketamine (2x Spravato® 28 mg nasal spray) — full drug profile →
0.9% saline solution nasal spray — full drug profile →

Conditions studied

Ketamine Treatment — all drugs for Ketamine Treatment →

Sponsor

Rupert Lanzenberger — full company profile →

Who can join

Adults 18 to 55, any sex, with Ketamine Treatment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subanesthetic ketamine is currently used as a rapid-acting antidepressant. It is an antagonist of the N-methyl-d-aspartate (NMDA) receptor, but former results indicate that its action also depends on the noradrenaline system and the locus coeruleus (LC). Based on this known impact of ketamine on the sympathetic nervous system the aim of this study is to investigate the effects of intranasal esketamine on LC related attentional brain networks in task based functional MRI, to relate those attention network changes to behavioural measures and to predict ketamine related attention network changes by brain structure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sex, drugs, and arousal-two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity.
Klöbl M, Liebe T, Dörl G, Stöhrmann P, et al · · 2026 · PMID 41693798 · DOI 10.1177/20451253251406059

Verify or expand the search:

Other Rupert Lanzenberger trials

Trials by the same sponsor.

NCT06243783 — Impact of Stress on Brain Energy Metabolism · NA · recruiting
NCT03257397 — TBS in Major Depression · NA · unknown
NCT03485066 — Simultaneous PET/MR Imaging of Human Brain Plasticity · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05320120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rupert Lanzenberger
Last refreshed: 15 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05320120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing